TScan Therapeutics
TCRX
92 hedge funds and large institutions have $55.4M invested in TScan Therapeutics in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 19 reducing their positions, and 13 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 19
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
3% more funds holding
Funds holding: 89 → 92 (+3)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
7.86% less ownership
Funds ownership: 84.59% → 76.73% (-7.9%)
56% less capital invested
Capital invested by funds: $126M → $55.4M (-$70.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.11M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.04M |
| 3 |
CC
Checkpoint Capital
San Francisco,
California
|
+$566K |
| 4 |
Millennium Management
New York
|
+$500K |
| 5 |
JP Morgan Chase
New York
|
+$429K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$9.38M |
| 2 |
TAM
Tocqueville Asset Management
New York
|
-$506K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$404K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$352K |
| 5 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$335K |
TCRX Hedge Fund Activity: Q1 2025 in Review
92 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q1 2025, worth a combined $55.4M — down 56% from $126M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TCRX positions and 13 closed out — a net gain of 3 holders — while 33 added to existing stakes and 19 trimmed.
The largest buyer was BVF Inc, adding an estimated $4.11M. The largest seller was EcoR1 Capital, cutting an estimated $9.38M.
- 92 institutional investors held TScan Therapeutics (TCRX) as of Q1 2025, up from 89 in Q4 2024.
- Funds reported $55.4M of TScan Therapeutics stock for Q1 2025, down 56% quarter-over-quarter.
- 16 funds opened new TScan Therapeutics positions in Q1 2025 and 13 closed out, a net change of +3 holders.
- The largest TScan Therapeutics buyer in Q1 2025 was BVF Inc, an estimated $4.11M added.
- The largest TScan Therapeutics seller in Q1 2025 was EcoR1 Capital, an estimated $9.38M sold.
Based on aggregated 13F filings for Q1 2025.